Ligand Pharmaceuticals Inc. has followed its sale of Avinza rights for $265 million to King Pharmaceuticals Inc. by offloading three more drugs - the rest of the firm's commercial operations - to Eisai Co. Ltd. for $205 million plus royalties, in what Ligand called an ongoing "shareholder value maximization process." (BioWorld Today)

While MedImmune Inc. awaits word from the FDA on the supplemental biologics license application for its flu vaccine and seeks ways to pump sales of Synagis, the firm signed a potential $500 million deal with Infinity Pharmaceuticals Inc. focused on small-molecule cancer drugs targeting heat-shock protein 90 (Hsp90) and the Hedgehog cell-signaling pathway. (BioWorld Today)